A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease

Audrey Bennett; Lauren Evers Carlini; Caroline Duley; Ailish Garrett; Kim Annis; Julianne Wagnon; Robin Dalal; Elizabeth Scoville; Dawn Beaulieu; David Schwartz; Sara Horst

doi:10.1093/crocol/otaa013

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease

Crohns Colitis 360. 2020 Jan;2(1):otaa013. doi: 10.1093/crocol/otaa013. Epub 2020 Feb 27.

Authors

Audrey Bennett^{1

2}, Lauren Evers Carlini^{1

3}, Caroline Duley^{1

2}, Ailish Garrett^{1

2}, Kim Annis^{1

2}, Julianne Wagnon^{1

2}, Robin Dalal^{1

2}, Elizabeth Scoville^{1

2}, Dawn Beaulieu^{1

2}, David Schwartz^{1

2}, Sara Horst^{1

2}

Affiliations

¹ Deparment of Gastroenterology, Vanderbilt Univeristy Medical Center, Nashville, Tennessee, USA.
² Vanderbilt Gastroenterology Clinics, Nashville, Tennessee, USA.
³ Internal Medicine Clinic, Nashville, Tennessee, USA.

Abstract

Background: Ustekinumab was approved for moderate and severe Crohn's disease (CD) in 2016, but little is known about long-term outcomes.

Methods: A retrospective study evaluated all patients with CD treated with ustekinumab, including patients with reinduction. C-reactive protein (CRP), Harvey-Bradshaw Index (HBI), Short Inflammatory Bowel Disease (SIBDQ), and endoscopy outcomes were collected prospectively.

Results: Ninety-six patients received ustekinumab, resulting in improvement in CRP, HBI, and SIBDQ scores with 68% endoscopic improvement/remission. Thirty-four patients underwent reinduction, resulting in improved HBI and CRP.

Conclusions: Ustekinumab in refractory CD results in significant clinical and endoscopic improvement and reinduction may be a viable option to recapture response.

Keywords: Crohn disease; reinduction; response; ustekinumab.

Grants and funding

KL2 TR002245/TR/NCATS NIH HHS/United States